



## Role of Sneha kalpana (Oil based formulation) in the management of *Vataja Prameha (Vata predominance Prameha)* w.s.r. to *Khadira-kramuka kashaya siddha taila*

Amrit Godbole<sup>\*1</sup>, Abhinav<sup>1</sup>, Sweta K M<sup>2</sup>, Arpit Srivas<sup>3</sup>, Vandana Singh<sup>1</sup>, Pratyush Sharma<sup>1</sup>, Singh O P<sup>1</sup>, Tripathi J S<sup>1</sup>

<sup>1</sup>Faculty of Ayurveda, Institute of Medical Sciences, BHU, Varanasi-221005, Uttar Pradesh, India

<sup>2</sup>Dr Vijay Ayurvedic College, Kaithi, Varanasi, Uttar Pradesh, India

<sup>3</sup>UP State Government, Uttar Pradesh, India



### Article History:

Received on: 20 Feb 2021  
Revised on: 24 Mar 2021  
Accepted on: 25 Mar 2021

### Keywords:

Diabetes Mellitus,  
Metabolic Syndrome,  
Obesity,  
Prameha,  
Khadira-  
Kramukakashaya Siddha  
Tail

### ABSTRACT

Diabetes mellitus is a fast-growing pandemic. In India, the urban population is more prone to disease rather than the rural Indian population. Dietary habits, faulty lifestyle, and urbanization leading to reduced physical exercise may be responsible to a large extent. Indian system of medicine, namely *Ayurveda* cited a disease entity named *Prameha*. It is a clinical syndrome that includes various clinical conditions like, obesity, pre-diabetes, diabetes, and metabolic syndrome. The symptomatology, types, and sub-types mentioned in the context shows relevance with modern times rationale of free fatty acid and its role in peripheral insulin resistance. The article put an emphasis on those cases of chronic diabetes (DM type 2) which becomes insulin dependent in later phase of life and its coherence with *Vatolwana prameha of kaphaja* and *pittaja* variety (*Kaphaja* and *Pittajaprmeha* with predominant *Vata*). This review article focuses on the Ayurvedic management of chronic insulin dependent type 2 diabetics. Various research papers indexed in Pubmed, SCOPUS, and Web of Science was deeply studied and cited appropriately in the article. The closest possible correlation of modern and Ayurveda principles and their relevance in the present time is tried to be drawn. The treatment protocol given in Ayurveda texts is scientific enough to be taken into consideration for making it as the first-line treatment of not only diabetes mellitus but also in the cases of obesity and metabolic syndrome.

### \*Corresponding Author

Name: Amrit Godbole  
Phone: +91 7408859248  
Email: [amritgodbole2@gmail.com](mailto:amritgodbole2@gmail.com)

ISSN: 0975-7538

DOI: <https://doi.org/10.26452/ijrps.v12i2.4742>

Production and Hosted by

IJRPS | [www.ijrps.com](http://www.ijrps.com)

© 2021 | All rights reserved.

### INTRODUCTION

*Prameha* as mentioned in ancient Ayurveda texts depicting a disease of *Mutravaha sansthana* (Urinary system) but most importantly it is a disease of metabolism. Urinary tract related symptoms are frequently associated at every stage of the disease ([Puranik and Patwardhan, 2012](#)). The classical symptom representing of *Prameha* is passage of excess amount of Turbid urine (*Prabhuta Avila mutrata*) ([Tewari et al., 2017](#)). *Prameha* also derives its name from its character similar to Polyuria ([Shrikantha, 2004](#)). The ancient Ayurveda texts scripted *Prameha roga* (Disease) in a much elaborated manner. Detailed descrip-

tions on *Prameha* are available in the NCBI book database (Morandi et al., 2011; Sharma and Chandola, 2011a,b). This is the reason why Acharya Charaka mentioned it as one among the *Ashta maha gada* (Eight major Ailments). *Prameha* is not a single disease rather it is a complex phenomenon covering a number of conditions ranging from obesity to pre-diabetes, diabetes mellitus, thyroid dysfunctions and metabolic syndrome (Sharma and Chandola, 2011a,b). With growing economy and disturbed lifestyle, the problem has become so grave that India is supposed to be the diabetes capital of the world (Pandey and Sharma, 2018). In Diabetes Atlas 2015 it was said, in India presently 69.2 million patients is expected to rise to 123.5 million by 2040 unless prompt prophylactic measures are taken. Onset of Diabetes in India is 2 decades ahead contrast to rest of the world. This further validates the possibility of a more combative diabetes phenotype prevailing to this very part of the world (King et al., 1998; Mohan et al., 2007; Dutta and Mukhopadhyay, 2018).

### **Dosha (Three fundamental bodily humours - Vata, Pitta, and Kapha) and Dushyas (Body tissues and other elements) in Prameha roga**

Overeating of *Kapha Vardhaka Ahara* (*Kapha* dominant diet) together with sedentary life-style, day time sleeping, lack of exercise, faulty dietary habits, etc. are the varied etiological factors for *Sthaulya* (Obesity). Overindulgence in these etiological factors finishes up in increase in *Guru* (Heavy), *Snigdha* (Slimy), *Manda* (Dull), *Sthira* (Steady) *Gunas* (Properties) within the body which ends up into *Kaphaja vikaras* (*Kapha* dominant diseases). Excessive formation of *Meda dhatu* (Adipose tissue) is a persistent feature of *Sthaulya* (Obesity). *Medo vridhi* (Adipose deposition) in a *Sthula* (Obese) person is of two types: (i) *Baddha Meda Vriddhi* (Bounded lipids), (ii) *Abaddha Meda Vriddhi* (Circulating lipids). The aetiology of *Prameha* is analogous to *Sthaulya* (Obesity) and goes hand in hand (Singh et al., 2014).

*Prameha* is a *Tridoshaja Vyadhi* (Three fundamental bodily humours - *Vata*, *Pitta*, and *Kapha*) but it is basically a disease with dominance of *Kapha dosha* (Sharma and Chandola, 2011a,b). *Prameha* has Ten *Dushyas* (Body tissues and other elements) viz. *Rasa* (Plasma), *Rakta* (Blood), *Mamsa* (Muscles), *Meda* (Adipose), *Majja* (Marrow), *Shukra* (Semen), *Oja* (Immunity), *Ambu* (Water), *Vasa* (Fat), *Lasika* (Lymph). The *dosha* (Principal systems functions - *Vata*, *Pitta*, and *Kapha*) and the *dhatu* (Tissue) involved in the pathogenesis of *Prameha roga* (Disease) bears liquid tendency i.e. the liquefied nature

of *Kapha dosha* (Principal systems functions - *Vata*, *Pitta*, and *Kapha*) involved in the pathogenesis of *Prameha roga* (Disease).

At the same time, the primary *dushya* (Body tissues and other elements) involved in the pathogenesis of *Prameha* are *Meda* (Adipose), *Mamsa* (Muscle) and *Shariraj Kleda* (Bodily wetness) (Pandey, 2009). The *Meda dhatu* (Adipose tissue) is actually the *Abaddha Meda* (Circulating lipids) representing the fat which is mobile in nature and circulates freely in the plasma in the form of plasma lipids. Free fatty acids (FFA) are one important link between obesity, insulin resistance, and Type 2 diabetes mellitus (Valaiyapathi et al., 2020).

### **Types of Prameha**

In Ayurveda text, *Prameha rogi* (Patient) are classified into two categories i.e. *Sthula* (Obese)/*Balwan* (Strong) and *Krishna* (Lean) / *Durbala* (Weak) and *Sahaja* (Hereditary) and *Apathyanimitaja* (Acquired). *Sahaja prameha* (Hereditary) is due to *Beeja dosha* (Genetic anomaly) while *Apathyanimitaja prameha* (Acquired) is due to faulty dietary habit and lifestyle leading to *Sthaulya* (Obesity) (Tewari et al., 2017).

Depending upon the *Dosha* and *Dushya* involved, *Prameha* is classified into three categories.

1. Ten *Kaphaja Prameha* (*Prameha* with *Kapha* predominance) are considered *Sadhya* (Curable) due to similar nature of *Dosha* and *Dushya* (Principal systems functions - *Vata*, *Pitta*, and *Kapha* and body tissues and other elements) leading to which the treatment is quite easy.
2. Six *Pittaja Prameha* (*Prameha* with *Pitta* predominance) are considered as *Yapya* (manageable but not curable) i.e. recurrence occurs once treatment is put on hold due to opposite nature of both the *Dosha* and the *Dushyas*.
3. Four *Vataja Prameha* (*Prameha* with *Vata* predominance) are *Asadhya* (Incurable) (Pandey, 2009; Baruah and Gupta, 2002; Nanda et al., 2001).

### **Pathogenesis of Vataja Prameha (Prameha with Vata predominance)**

*Vataja Prameha* has three possible pathogenesis:

1. *Kapha-Pitta Kshinata* (Loss of *Kapha* - *Pitta dosha*) leading to *Vata prakopa* (vitiation of *Vata*)
2. *Dhatu Kshaya* (Tissue emaciation) as a result of chronicity of disease leading to *Vataprakopa* (vitiation of *Vata*)

3. Pure *Vata Prakopa* (Vitiating of *Vata*) due to etiological factors aggravating *Vata Dosha* causing *Dhatukshaya* (Loss of Body tissues), leading to *Vataja Prameha* (Prameha with *Vata* predominance).

Out of the three possibilities, first and second signifies the chronic nature of the disease. The chronicity leads to *Dhatukshaya* (Tissue emaciation) and the gateway to this is the *Dhatwagni Nasha* (Loss of metabolic energy at the tissue level), leading to loss of all the *Sapta dhatus* (Seven tissues), ultimately leading to *Ojakshaya* (Immuno-compromised status). *Ayurveda* and Contemporary science both supports the fact that newer the disease easier is its management. *Dhatu Kshaya* leads to *Vata Prakopa* which again leads to *Vishamagni* (disturbed metabolic fire) and a vicious cycle occurs. Thus this gives an insight towards the poor prognosis of *Vataja Prameha* of either category (Sharma and Chaudhary, 2014).

#### Selection of *Khadira* (Acacia catechu) and *Kramuka* (Areca nut) for the study

Acharya *Chakrapani* on his commentary over *charaka siddhi sthana* mentioned the properties and actions of any compound formulation or *Karma* follows the principles of *Prakritisamasamavaya* and *Vikritivishamasamavaya*. According to these principles *Samyoga* (combination) of many drugs in a compound formulation gives rise to some new properties and actions (*Vikritivishamasamavaya*) along with existence of the inherent one (*Prakritisamasamavaya*). Therefore, while considering the *Guna, Karma* of *Khadira Kramuka Kashaya Siddha Taila*, we should consider the *Guna, Karma* of their ingredients.

Acharya *Sushruta* wisely mentioned the use of *Khadira* (Acacia catechu) and *Kramuka* (Areca catechu) decoction in the management of *Madhumeha* (Chronic Diabetes mellitus). The decoction has *Kashaya* (Astringent) - *Tikta* (Bitter) *Rasa* (Tastes) and *Katu Vipaka* (Pungent post digestive effect). *Kashaya Rasa* (Astringent taste) has *Stambhana* (Suppression) properties. Thus by virtue of this property the decoction is capable of curbing excess micturition and through this the eventual loss of *Oja* (Immunity) is also restricted. It also absorbs the *Kleda* (Wetness), *Abaddha Meda* (Circulating lipids), *Vasa* (Fat) and *Kapha Dosha*, this reduces the peripheral insulin resistance which improves the disease status (Archana et al., 2015). *Kasaya* rasa not only reduces the peripheral insulin resistance as well as clinical manifestation of the disease. '*Tikta*' rasa in addition to *Kashayarasa*, has predominance of *Akasha* and *Vayumabhoota*. So it has ability of

permeate to *sushmastrotasas*. Due to this drug can reach at cellular level and help to reduce *meda* and *Kleda*. Thus, helps in breakdown of *Pramehasampranti* and reduces related symptoms. In pathogenesis of *Madhumeha*, *Vata Dosha* is predominant factor. For controlling of *Vata Dosha*, the contents of *Khadira Kramuka Kashaya Siddha Taila* have properties of *Snighdha*, *Rasayana* and *Yogavahi* effects.

Acacia catechu belongs to family Leguminosae and is found in various parts of Asia. The flavonoids from the hard wood of A. catechu have been used in many traditional medicine pharmaceutical products, especially in Asia, for a variety of purposes including anti-inflammatory, anti-virus, antibacterial, anti-cancer, and cardiovascular application. Acacia catechu commonly known as *Kattha* or *Khadira* is a member of leguminosae family found in various parts of Asia. The anti-inflammatory activity of wood extracts flavanoid from *Acacia* have been reported, may be due to its antioxidant properties (Stohs and Bagchi, 2015; Oliveira et al., 2020). *Khadira* (Acacia catechu) has anti-diabetic and anti-dyslipidemic properties (Ikarashi et al., 2011). An experimental study carried out on animal model of Type-2 Diabetes mellitus (T2DM) showed significant anti hyperglycemic activity. The Oral glucose tolerance test (OGTT) was carried out post sucrose load in normal rats and streptozocin induced diabetic rats (Eyth et al., 2019). The study showed that the aqueous as well as ethanolic extracts of *Khadira* (Acacia catechu) hard wood have marked ability to improve oral glucose tolerance comparable to standard anti-diabetic drug. In the same study, this was also established that *Khadira* (Acacia catechu) have the potential to prevent the secondary complications associated with T2DM (Srivastava et al., 2011). Thus Antioxidant, anti-inflammatory and anti-diabetic properties of *Khadira* (Acacia catechu) is well established. Its aqueous and ethanolic extract was studied and it was found to have potent antioxidant activity. This antioxidant nature of *Khadira* (Acacia catechu) was believed to be responsible for the anti-inflammatory activity in both in-vitro and in-vivo (Stohs and Bagchi, 2015).

*Khadira* (Areca catechu) belongs to family Arecaceae and is a species of palm found in various parts of Asia. *Khadira* (Areca catechu) is used in traditional medicine and as well known folk remedy for the treatment of Diabetes in southern parts of India. In Ayurvedic literature it has been mentioned that *Kramuka* (Areca nut) is widely used as *Pramehaghna* (Antidiabetes). Acharya *Sushruta* mentioned it in *Salsaradi gana* whereas Acharya *Vagbhata* mentioned it in *Asanadi gana*, both are dedicated to *Prameha* and have *Kapha-Medohara karma*

(Decreases *Kapha* and Anti-obesity property), as *Kapha* and *Meda* (Adipose tissue) are the root causes in initiating pathogenesis. Anti diabetic effect of *Khadira* (Areca catechu) flower extract was assessed in alloxan induced diabetic rats. Study revealed significant anti-diabetic activity of ethanolic and aqueous extract of *Khadira* (Areca catechu) flowers in animal model. The study was confirmed by significant restoring of biochemical parameters. The phytochemical study showed presence of phenolic content in both the extracts (Salehi et al., 2019).

### ***Khadira Kramuka Kashaya Siddha Taila* (Black catechu and Areca nut decoction based Oil)**

*Khadira kramuka kasaya siddha taila* is a new formulation based on the ancient idea of the two great saints of Ayurveda, *Acharya Charak* and *Acharya Susruta*. *Susruta Samhita* has mentioned the *Khadira kramuka kasaya* in the management of *Madhumeha* and *Acharya Charaka* has given the instruction to use Medicated oils and ghee prepared by processing with the decoctions and that should be administered to patients suffering from *Vatika Prameha*. The decoctions correct the vitiated *Medas* and *Kapha* and the aggravated *Vata* in these patients gets alleviated by the unctuous ingredients. So by merging the idea of these great saints we prepare a formulation named *Khadira kramuka kasaya siddha taila (KKST)* by classical method of *sneha kalpana* mentioned in Ayurveda and the quality analysis of prepared formulation is done in a CPCSEA certified lab as per the norms of API -II (Ayurvedic Pharmacopodia of India).

As stated above, *Khadira* (Areca catechu) and *Kramuka* (Areca nut) exhibit anti-diabetic as well as anti-dyslipidaemic properties. When the decoction of both has to be used in the cases of *Madhumeha* (Chronic diabetes mellitus) per se lean and thin chronic uncontrolled hyperglycaemic with comorbidities, we use a base of oil. As mentioned earlier in the text, the chronic PHs is the cases which are coherent with *Vata* predominant cases of *Prameha*. The drugs in the decoction balance the incoherence of *Doshas* and *Dushyas* while the Oil base mitigates the elevated *Vata dosha*. The Sesame oil is the best suited oil for medicinal use. The Anti-hyperglycemic effect of Sesame indicum oil is well established (Sankar et al., 2005).

Various studies have evaluated the anti hyperglycaemic effects of *Sesamum indicum*. An experimental study on Wistar albino rats done in controlled condition demonstrated that ethanolic extract of *Sesamum indicum* seeds has a potential effect on Hyperglycemia. The study was backed up with biochemical investigation like blood glucose, glycosy-

lated haemoglobin, serum insulin and liver glycogen levels, which showed that glucose level in streptozocin induced diabetic rats were reduced to near normal after treatment (Bhuvanewari and Krishnakumari, 2012).

Dietary saturated fatty acids (SFA) increase the risk for obesity and cardiovascular disease, whereas monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA) decrease those risks by modification of lipids (Hu et al., 2001). Studies have shown that Sesame oil is a rich source of mono unsaturated and poly unsaturated fatty acids (Goodman et al., 1988).

### **Advantages of *Taila Kalpana***

Formulations prepared from the *Taila* enhance shelf life, having high bio-availability, enhances drug absorption ensures absorption of active principles of ingredients. It enhances the therapeutic effect via the nutritive and *Rasayana* effect of *Til taila*. The water soluble as well as fat-soluble active principles can be transformed into oil media and this addition of properties of material made the *Taila* potent and effective.

### **Method of Preparation**

Ingredients of *Khadiraa KramukaKashayaSiddha Taila* has been given in Table 1 (Srivastava, 2003).

1. 1 part of *kalka dravya* (paste of herbs- *Khadi-  
raa&Kramuka* )
2. 4 parts of oil (*Til taila*)
3. 16 parts of *drava* (*kwatha* of *Khadi-  
raa&Kramuka*)

These are to be mixed together & heat on *Mandagani* to prepare the medicated *Taila*. Then it is filtered and stored.

### **DISCUSSION**

*Vataja prameha* is said to be untreatable, but here a question arises, which *Vataja prameha* is treatable then. *Acharya Charak* in *Charak samhita* clarified that only those *Vataja prameha* in which exacerbation of *Vata* is secondary to reduced *Kapha* and *Pitta* is the one which is manageable rest other *Vataja Prameha* due to the vitiation of pure *Vata*, is not treatable (Pandey, 2009).

Out of above mentioned three possible pathogenesis of *Vataja prameha* (*Prameha* with *Vata* predominance), first and second pathogenic pathway is compared with the long standing Type 2 Diabetes Mellitus (T2DM) while the third is comparable to T1DM.

**Table 1: Ingredients of Khadiraakramuka KashayaSiddha Taila**

S.No.	Name of Drug
1.	Khadiraa(Acacia catechu)
2.	Kramuka(Areca catechu)
3.	Tila(Sesamum indicum)

**Table 2: Resemblance between types of Prameha and Diabetes Mellitus**

Prameha	Diabetes Mellitus
<i>Sthula/ Balwan</i> (Obese/ Strong)	T2DM
<i>Krish/ Durbala</i> (Lean/ Weak)	T2DM with chronicity /Later phase of MODY
<i>Sahaj prameha</i> (Hereditary)	T1DM
<i>Apathyanimitajja</i> (Acquired)	T2DM

The aforesaid first and second pathogenesis is somewhat two stages of one clinical condition. The first one is the early stage type 2 DM while the second one is the later stage where dosing of OHA increases and still fair control is not reached and ultimately these patients are put on Insulin therapy, this makes a large number of "OHA non-responding" group of patients which brings a new category of diabetics called as Insulin dependent type 2 diabetes mellitus (IDT2DM).

The chronic, uncontrolled or poorly controlled hyperglycaemia leads to multiple systemic illness e.g. CKD, diabetic retinopathy etc. and has associated higher risk of mortality (Sperry et al., 2009). Conventional system of medicine had progress a lot in the field of medicine still a promising management of diabetes mellitus is not available. Present medical solutions available; ensure maintaining optimum insulin level in the body by means of OHA or by means of Insulin therapy. But a complete reversal of the pathogenesis is not taking into account. Here is where Ayurveda holistic management scheme comes into play. Starting from *Nidana parivarjana* (Elimination of basic cause) and treatment as per *Kriya Kala* (Stages of disease progress) is of huge importance.

#### Staging of Prameha and its modern parlance

The *Sthula pramehi* (Obese diabetics) in the early stage, say ( $S_0$ ) simulates with the Pre-diabetic phase which can be reversed through diet and exercise only. Once the patient slips into Persistent hyperglycemia (PH) which is manageable through OHA's (Oral hypoglycaemic agents) in conventional system of medicine say stage 1 ( $S_1$ ), certain medications are necessary to reverse the pathogenesis. The  $S_1$  patients need to be treated with evacuative (*Shodhana*) and Pacificatory (*Shamana*) measures. Repeated *Shodhana* and *Shamana* along with diet

and exercise practices pacify the enhanced *Kapha dosha* and also stabilises the *Dushyas* (Body tissues and other elements).

The *Prameha rogi* (Patient) with *Hinabala* (Weak body strength) or the *Krishapramehi* (lean and thin Patient) are the patients of T2DM with chronicity leading to *Dhatukshaya* (Loss of Body tissues). These *Prameha rogi* are hard to manage as in these patients, exercise and diet restrictions have a limited role. These patients are analogous to chronic uncontrolled hyperglycemic with comorbidities, for say stage 2 of T2DM ( $S_2$ ).

Our ancient sages mentioned 20 types of *Mutra atipravritti janyaroga* (Disease associated with excessive urine output) as *Prameharoga* (Disease). In Ayurveda, *Prameha* is the disease with a prodrome of polyuria and the name given to these types depends upon their physical properties. *Madhumeha* is end stage of *VatajaPrameha* that can occur as the terminal stage of type 2 diabetes, or as type 1 diabetes. The latter is defined as *JatahPramehiMadhumehino* (Hereditary DM) (Sharma and Chandola, 2011a,b). At the same time nomenclature was so wisely done that it also depicted the gravity of the clinical state. e.g. *Ojomeha* refers to Immuno-compromised state (Pandey, 2009). *Oja* (Immune) is the essence of all the *Dhatus* (Body tissue) and is referred as *Bala* (Strength) by *AcharyaSushruta*. It provides the innate immunity that produces resistance against many diseases (Ranade and Acharya, 2015). Therefore we understand the seriousness of PH with co-morbidities which were very well known to our ancient sages. The concept of immunosuppression through various metabolic pathways due to persistent hyperglycemia is a well known phenomenon (Graves and Kayal, 2008). This *Madhumeha* or *Ojo meha* or *Kshaudra meha* due

to progressive illness is the S<sub>2</sub> of T2DM. These patients need promotive (*Brihmana*) treatment. The management of S<sub>2</sub> patients focuses on the utilisation of the decoctions mentioned in the context of *Prameharoga* (Diabetes), to be cooked with Oils and *Ghritas* (Clarified butter). By doing so, the drugs in the decoctions diminish the *Dushta medas* (Impure lipids) and *Kapha*, whereas the Oil and Ghee (Clarified butter) pacifies *Vata* (Pandey, 2009). Resemblance between types of *Prameha* and Diabetes Mellitus has been given in Table 2.

### Mode of Action of Khadiraa Kramuka Kashaya Siddha Taila

*Khadiraa Kramuka Kashaya Siddha Taila* has a maximum of *Kashaya Rasa* followed by *Tikta Rasa* and *Katu vipaka*, *Kashaya Rasa*, *Tikta rasa* helps in *Sthireekarana* of *Dhatu*s and also does *KledaU-pashoshana*. *Kashaya Rasa* is helpful in *Shareea Kleda Harana*, *Laghu*, *Rooksha Guna* produces *Rookshana* and *Shoshana* effect and they are having opposite qualities to that of *Kapha* and *Medas* which is the main entity of the Pathogenesis of *Madhumeha*. *Kasaya Rasa* acts as a controller of excessive urination; *Dhatu kasaya* and *OjaKsaya* through urine by their *Stambhana* properties. It absorbs *Kleda*, *Meda*, *Vasa* and *Kapha Dosha*.

### CONCLUSION

*Prameha roga* is not a single clinical condition nor could it be compared to any one disease set. Knowledge of *Kriya kala* (Stage of a diseases progress) and its application in learning the disease process is of very importance in *Prameha*. Broad classification given by our ancient sages is needed to be elaborated and scrutinized in present era. Stage wise medical and non medical management will not be able to just prevent but also cure the diabetes which the conventional medical system is not able till today. The line of treatment mentioned in Ayurveda texts and the drugs indicated in the clinical conditions are effective even in today's context. Only the need is, to evaluate it according to the advance clinical and biochemical parameters.

### Funding Support

The authors declare that they have no funding support for this study.

### Conflict of Interest

The authors declare that there is no conflict of interest for this study.

### REFERENCES

- Archana, T. P., Prashasth, M. J., Muralidhara 2015. Khadiraa Kramuka Kashaya Prayoga In Madhumeha W.S.R. To Type II Diabetes Mellitus-A Clinical Study. *International Ayurvedic Medical Journal*, 3(7):1934-1938.
- Baruah, D., Gupta, O. P. 2002. A comparative study of Prameha Roga from the Brihatrayee. *Bulletin of the Indian Institute of History of Medicine (Hyderabad)*, 32:93-107.
- Bhuvanewari, P., Krishnakumari, S. 2012. Antihyperglycemic potential of Sesamum indicum (Linn) seeds in streptozotocin induced diabetic rats. *Int J Pharm Pharm Sci*, 4(1):527-531.
- Dutta, D., Mukhopadhyay, S. 2018. Novel diabetes subgroups. *The Lancet Diabetes & Endocrinology*, 6(6):438.
- Eyth, E., Basit, H., Smith, C. J. 2019. Glucose Tolerance Test. [Updated 2019 Jun 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
- Goodman, D. S., Hulley, S. B., Clark, L. T., Davis, C. E., Fuster, V., Larosa, J. C., Gordon, D. 1988. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. *Archives of Internal Medicine*, 148(1):36-69.
- Graves, D. T., Kayal, R. A. 2008. Diabetic complications and dysregulated innate immunity. *Frontiers in Bioscience*, 13(4):1227-1239.
- Hu, F. B., Manson, J. E., Willett, W. C. 2001. Types of Dietary Fat and Risk of Coronary Heart Disease: A Critical Review. *Journal of the American College of Nutrition*, 20(1):5-19.
- Ikarashi, N., Toda, T., Okaniwa, T., Ito, K., Ochiai, W., Sugiyama, K. 2011. Anti-Obesity and Anti-Diabetic Effects of Acacia Polyphenol in Obese Diabetic KKAY Mice Fed High-Fat Diet. *Evidence-Based Complementary and Alternative Medicine*, 2011:1-10.
- King, H., Aubert, R. E., Herman, W. H. 1998. Global Burden of Diabetes, 1995-2025: Prevalence, numerical estimates, and projections. *Diabetes Care*, 21(9):1414-1431.
- Mohan, V., Sandeep, S., Deepa, R., Shah, B., Varghese, C. 2007. Epidemiology of type 2 diabetes: Indian scenario. *The Indian Journal of Medical Research*, 125(3):217-230.
- Morandi, A., Tosto, C., Sartori, G., Sarsina, P. R. D. 2011. Advent of a Link between Ayurveda and Modern Health Science: The Proceedings of the First International Congress on Ayurveda,

- “Ayurveda: The Meaning of Life—Awareness, Environment, and Health” March 21-22, 2009, Milan, Italy. *Evidence-Based Complementary and Alternative Medicine*, pages 1–7.
- Nanda, G. C., Padhi, M. M., et al. 2001. Screening of Madhumehaghna (anti diabetic) plants in Vrihatrayee. *Bulletin of the Indian Institute of History of Medicine (Hyderabad)*, 30(1):15–26.
- Oliveira, C. S. D., Moreira, P., Resende, J., Cruz, M. T., Pereira, C. M. F., Silva, A. M. S., Santos, S. A. O., Silvestre, A. J. D. 2020. Characterization and Cytotoxicity Assessment of the Lipophilic Fractions of Different Morphological Parts of *Acacia dealbata*. *International Journal of Molecular Sciences*, 21(5):1814.
- Pandey, P. T. K. 2009. Chaturvedi Gorakhnath Agnivesha, Charak Samhita Sutra sthan Varanasi: Chaukhambha Bharti Academy.
- Pandey, S., Sharma, V. 2018. World diabetes day 2018: Battling the Emerging Epidemic of Diabetic Retinopathy. *Indian Journal of Ophthalmology*, 66(11):1652–1653.
- Puranik, A., Patwardhan, B. 2012. Ayurveda and metabolic diseases: the whole is greater than the sum of the parts. pages 443–456. Nutritional and therapeutic interventions for diabetes and metabolic syndrome. Elsevier Inc./Academic, Amsterdam/Boston.
- Ranade, A. V., Acharya, R. 2015. Concept of oja vis -a -vis endoplasmic reticular function: An approach to decode the holistic view. *Indian Journal of Health Sciences*, 8(2):109–114.
- Salehi, B., Ata, A., et al. 2019. Antidiabetic Potential of Medicinal Plants and Their Active Components. *Biomolecules*, 9(10):551.
- Sankar, D., Sambandam, G., Rao, M. R., Pugalendi, K. V. 2005. Modulation of blood pressure, lipid profiles and redox status in hypertensive patients taking different edible oils. *Clinica Chimica Acta*, 355(1-2):97–104.
- Sharma, H., Chandola, H. M. 2011a. Prameha in Ayurveda : Correlation with Obesity, Metabolic Syndrome, and Diabetes Mellitus. Part 1–Etiology, Classification, and Pathogenesis. *The Journal of Alternative and Complementary Medicine*, 17(6):491–496.
- Sharma, H., Chandola, H. M. 2011b. Prameha in Ayurveda : Correlation with Obesity, Metabolic Syndrome, and Diabetes Mellitus. Part 2–Management of Prameha. *The Journal of Alternative and Complementary Medicine*, 17(7):589–599.
- Sharma, V., Chaudhary, A. 2014. Concepts of Dhatu Siddhanta (theory of tissues formation and differentiation) and Rasayana; probable predecessor of stem cell therapy. *AYU (An International Quarterly Journal of Research in Ayurveda)*, 35(3):231–231.
- Shrikantha, K. R. M. 2004. Sushruta Samhita of Sushruta. Editor (reprint edition), Varanasi: Choukhambha Orientalia.
- Singh, J. P., Tiwari, S., Antiwal, M. 2014. Clinical evaluation of Lekhaniya Kashaya Vasti in the management of Sthaulya (obesity). *AYU (An International Quarterly Journal of Research in Ayurveda)*, 35(1):28–34.
- Sperry, J. L., Frankel, H. L., Nathens, A. B., O’keefe, G. E., Cuschieri, J., Moore, E. E., Maier, R. V., Minei, J. P. 2009. Characterization of Persistent Hyperglycemia: What Does It Mean Postinjury? *Journal of Trauma: Injury, Infection & Critical Care*, 66(4):1076–1082.
- Srivastava, S. 2003. Acharya Sarngadhar’s Sgarngdhar Samhita, Chaukhamba Orientalie. 3rd Edition, Page no. 215.
- Srivastava, S. P., Mishra, A., Bhatia, V., Narendar, T., Srivastava, A. K. 2011. *Acacia catechu* hard wood: potential anti-diabetic cum anti-dyslipidemic. *Medicinal Chemistry Research*, 20(9):1732–1739.
- Stohs, S. J., Bagchi, D. 2015. Antioxidant, Anti-inflammatory, and Chemoprotective Properties of *Acacia catechu* Heartwood Extracts. *Phytotherapy Research*, 29(6):818–824.
- Tewari, P., Dabas, R., Chaudhary, N. 2017. Critical Study of Madhumeha in Ayurveda: A Review. *International Journal of Research in Ayurveda & Pharmacy*, 8(5):117–121.
- Valaiyapathi, B., Gower, B., Ashraf, A. P. 2020. Pathophysiology of Type 2 Diabetes in Children and Adolescents. *Current Diabetes Reviews*, 16(3):220–229.